This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events.
Single-centre, open-label phase 2 study at Fudan University Shanghai Cancer Center. Participants were women aged 18-70, ECOG 0-1, with untreated metastatic or recurrent TNBC. Five cohorts combined a Fudan subtype classification with genomic biomarkers. Within that strategy, 139 participants were randomised to matched additions to nab-paclitaxel (69) or nab-paclitaxel alone (70). This is a different classifier from Lehmann TNBCtype-4.
The primary comparison was investigator-assessed progression-free survival in the pooled intention-to-treat groups. At the 31 May 2023 cutoff, median follow-up was 22.5 months (interquartile range 15.2-29.0). It tested a package of classification, matching rules and regimens; it did not separately establish each component's effect.
Evidence that a particular subtype-linked treatment strategy can be tested prospectively. Keep the classifier, genomic rules, population, comparator, endpoint and harms attached to the result.
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer (TNBC).
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares TNBC molecular subtyping, Triple-negative breast cancer (TNBC).
Shares TNBC molecular subtyping, Triple-negative breast cancer (TNBC).
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/